Caribou Biosciences Sees Unusually High Options Volume (NASDAQ:CRBU)

Caribou Biosciences, Inc. (NASDAQ:CRBU) saw some unusual options trading activity on Monday. Stock investors bought 2,867 call options on the stock. This represents an increase of 726% compared to the average daily volume of 347 call options.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CRBU. Next Capital Management LLC acquired a new stake in shares of Caribou Biosciences during the second quarter worth $25,000. Creative Planning acquired a new position in Caribou Biosciences in the second quarter valued at $25,000. R Squared Ltd bought a new stake in Caribou Biosciences during the third quarter valued at $29,000. Hudson Bay Capital Management LP acquired a new stake in Caribou Biosciences during the 2nd quarter worth about $30,000. Finally, Savant Capital LLC bought a new position in shares of Caribou Biosciences in the 2nd quarter worth about $36,000. Institutional investors and hedge funds own 77.51% of the company’s stock.

Caribou Biosciences Trading Down 0.6%

NASDAQ CRBU opened at $1.76 on Wednesday. The firm has a market capitalization of $164.51 million, a PE ratio of -1.04 and a beta of 2.60. The business’s 50-day moving average price is $2.24 and its two-hundred day moving average price is $1.84. Caribou Biosciences has a 12 month low of $0.66 and a 12 month high of $3.54.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. Caribou Biosciences had a negative return on equity of 69.85% and a negative net margin of 1,690.45%.The company had revenue of $2.20 million during the quarter, compared to the consensus estimate of $1.94 million. As a group, analysts forecast that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CRBU has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, October 8th. Citigroup increased their price target on Caribou Biosciences from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 3rd. Wall Street Zen raised Caribou Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 24th. HC Wainwright upped their target price on Caribou Biosciences from $3.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Finally, Truist Financial set a $7.00 price target on Caribou Biosciences in a research note on Tuesday, November 4th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $8.75.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.